Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 28, 2024
Daily News
August 28, 2024
- Panel Conditionally OKs Change to Allow Use of Abortion Pill at Clinics Without Beds
August 28, 2024
- Japan Panel Clears Amgen’s TED Med, Rexulti for Alzheimer’s Agitation and More
August 28, 2024
- Regeneron to Hire 73 Rhinology Sales Reps to Back Dupixent Label Expansion
August 28, 2024
- High-Dose Mecobalamin Now in Line to Become Japan’s 1st ALS Med in 9-Plus Years
August 28, 2024
- Sanofi Curbs Supply of Ultra-Fast Acting Insulin Biosimilars in Japan
August 28, 2024
- MHLW Sets Global Health Vision to Enhance Drug Innovation Ecosystem
August 28, 2024
- A Time for Patience - 5: Focus Turning to Early and Preclinical ALS Treatment, TDP-43 as New Target
August 28, 2024
- Sakigake Tags Granted to GSK’s Bepirovirsen, Boehringer’s Nerandomilast
August 28, 2024
- PNH Drug PiaSky Approved in Europe: Roche/Chugai
August 28, 2024
- Astellas’ Hot Flash Drug Now in Global PIII for Women with Breast Cancer
August 28, 2024
- Guardant Liquid Biopsy Test Approved as CDx for Amivantamab Combo Therapy
August 28, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…